Itraconazole Slavia

Itraconazole, the active ingredient in Itraconazole Slavia, is a azole antifungal presented as an oral formulation for systemic use. It treats a range of invasive and superficial fungal infections—including blastomycosis, histoplasmosis, aspergillosis and candidiasis—when prescribed by a qualified healthcare professional.

GNH USA supplies Itraconazole Slavia as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide, with sourcing from the European Union market.

Itraconazole is used to treat systemic and localized fungal infections by targeting the causative organisms.

Blastomycosis: eradicates infection and prevents dissemination. Histoplasmosis: clears pulmonary and disseminated disease. Aspergillosis: controls invasive and chronic forms. Candidiasis: treats systemic candidemia and deep‑tissue infections. Dermatophytosis: resolves skin and nail fungal infections. Sporotrichosis: eliminates the pathogen in cutaneous and disseminated disease.

Itraconazole may cause a range of adverse reactions, which are classified by frequency and severity.

Common Side Effects: - Nausea and vomiting. - Abdominal discomfort or pain. - Headache. - Rash or pruritus. - Altered taste sensation.

Serious or Rare Side Effects: - Hepatotoxicity, including severe liver injury. - Congestive heart failure exacerbation. - Severe skin reactions such as Stevens‑Johnson syndrome. - Visual disturbances. - Cardiac arrhythmias.

Before initiating therapy, clinicians should evaluate patient‑specific risk factors and monitor for potential complications. - Liver monitoring: assess hepatic function before and during treatment. - Drug interaction review: evaluate concomitant medications for CYP3A4 interactions. - Pregnancy: safety not established; avoid unless benefit outweighs risk. - Heart failure: use with caution in patients with reduced ejection fraction. - Storage: Store at ambient temperature below 25 °C: keep in original packaging, protect from moisture.

Itraconazole has a notable potential for drug‑drug interactions that require careful management.

Major Interactions (Avoid): - Rifampin: induces metabolism, reducing itraconazole exposure. - St. John’s wort: strong CYP3A4 inducer, markedly lowering drug levels. - Ketoconazole: competitive inhibition may increase toxicity.

Moderate Interactions (Monitor Closely): - Warfarin: may enhance anticoagulant effect, requiring INR monitoring. - Phenytoin: can alter plasma concentrations of both agents. - Digoxin: increased levels possible, monitor cardiac function.